Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

Awareness of suffering of advanced liver disease in patients with T2D is remarkably low

The aim of the present population-based cross-sectional study is to estimate the awareness of liver disease among patients with T2D and whether it differs according to the degree of liver fibrosis estimated by transient elastography. The authors included all patients with T2D that participated in the 2017-2018 cycle of the NHAHES Survey and underwent...
Read MoreAwareness of suffering of advanced liver disease in patients with T2D is remarkably low

NAFLD burden in Australia, 2019-2030

The burden of NAFLD/NASH manifests in increasing levels of advanced liver disease and primary liver cancer in Australia. L. A. Adams et al. (The University of Western Australia, Perth, Australia) used a Markov model to forecast NAFLD burden in Australia through 2030. Prevalent NAFLD cases were projected to increase 25% from the current...
Read MoreNAFLD burden in Australia, 2019-2030

NAFLD and severe fibrosis are associated with to a high CV risk profile

G. Pennisi et al. (Università di Palermo, Italy) aimed to evaluate the impact of fatty liver and fibrosis on cardiovascular risk in a general population. They recruited 542 subjects included in the community-based ABCD (Alimentazione, Benessere Cardiovascolare e Diabete) study...
Read MoreNAFLD and severe fibrosis are associated with to a high CV risk profile

Sequential combination of NIS-4, MACK-3, and FAST scores

For Y. J. Zhou, et al., there is an urgent need to identify patients who are at risk of developing NASH. Traditional, non-invasive tests have been developed to identify either NASH or advanced fibrosis. However, these tests do not accurately detect patients who are at risk of NASH.
Harrison et al. developed and validated the NIS4 test that provides...
Read MoreSequential combination of NIS-4, MACK-3, and FAST scores

Epidemiology: NAFLD from 1999 to 2018 in China

For J. Zhou et al. (Wuhan University, China), NAFLD has become the most prevalent liver disorder in China but has not received sufficient attention. NAFLD-related advanced liver disease and its mortality along with its overall disease burden are expected to increase substantially. In their meta-analysis, the authors summarise eight...
Read MoreEpidemiology: NAFLD from 1999 to 2018 in China

NIS4 for non-invasive diagnosis of NASH and liver fibrosis

S. A. Harrison et al. (University of Oxford, UK) report the development and validation of a blood-based diagnostic test to non-invasively rule in and rule out at-risk NASH. In their prospective derivation and global validation study, derivation was done in the discovery cohort, which comprised 239 prospectively recruited patients with...
Read MoreNIS4 for non-invasive diagnosis of NASH and liver fibrosis

PPARs as candidates for the treatment of NAFLD

The prevalence of NAFLD is dramatically increasing in developed countries, but no approved therapy is available. Most of the current pharmacological strategies target comorbidities, such as manifestations of metabolic syndrome. In addition, none of used medications improve fibrosis, which is the strongest indicator of mortality in NAFLD...
Read MorePPARs as candidates for the treatment of NAFLD

OSA with NAFLD in patients with obesity: an observational study

A growing amount of evidence has correlated obstructive sleep apnea (OSA) with the presence of NAFLD and it has been demonstrated a direct association between the severity of the former and the progression of the latter. Thus, OSA patients should be screened for the presence and severity of NAFLD...
Read MoreOSA with NAFLD in patients with obesity: an observational study